ArticleEndocrine-related cancer2019
The molecular genetic make-up of male breast cancer.
Article in Endocrine-related cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.Breast cancer research and treatment · 2022Trial
- Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.Breast cancer research and treatment · 2021Trial
- Multiplatform single-cell and spatial transcriptomics reveal sex-specific malignant states and architecture in male breast cancer.Science advances · 2026Article
- Male Breast Carcinoma in an Elderly Patient: A Rare Presentation and the Importance of Individualized Management.Cureus · 2026Article
- Targeted next-generation sequencing reveals genomic differences between male and female breast cancer.Translational cancer research · 2025Article
- Current Perspectives on Non-Metastatic Male Breast Cancer: Genetics, Biology, and Treatment Advances: A Systematic Review.Cancers · 2025Review
- Clinical Characteristics and Survival Trends of Male Breast Cancer in the United States: A Propensity Score Matched Analysis.Journal of personalized medicine · 2025Article
- Clinical characteristics of male patients with breast cancer in the Latino population.Breast cancer research and treatment · 2025Article
- HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.Scientific reports · 2025Article
- Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective.Oncology research · 2025Review
- Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes.Breast cancer research : BCR · 2024Article
- Exploring the One Health Paradigm in Male Breast Cancer.Journal of mammary gland biology and neoplasia · 2024Review
- Gender-Specific Genetic Predisposition to Breast Cancer:Cancers · 2024Review
- Risk factors for male breast cancer.American journal of translational research · 2023Review
- Analysis of the Clinical Advancements forCancers · 2022Review
- Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.Frontiers in oncology · 2022Article
- Case Report: Response to Immunotherapy and Anti-Androgen Therapy in Male Occult Triple-Negative Breast Cancer.Frontiers in oncology · 2022Article
- Male breast cancer: an update.Virchows Archiv : an international journal of pathology · 2022Review
- Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 11 institutions in 2 countries.
Funding
Abstract
Male breast cancer (MBC) is extremely rare and accounts for less than 1% of all breast malignancies. Therefore, clinical management of MBC is currently guided by research on the disease in females. In this study, DNA obtained from 45 formalin-fixed paraffin-embedded (FFPE) MBCs with and 90 MBCs (52 FFPE and 38 fresh-frozen) without matched normal tissues was subjected to massively parallel sequencing targeting all exons of 1943 cancer-related genes. The landscape of mutations and copy number alterations was compared to that of publicly available estrogen receptor (ER)-positive female breast cancers (smFBCs) and correlated to prognosis. From the 135 MBCs, 90% showed ductal histology, 96% were ER-positive, 66% were progesterone receptor (PR)-positive, and 2% HER2-positive, resulting in 50, 46 and 4% luminal A-like, luminal B-like and basal-like cases, respectively. Five patients had Klinefelter syndrome (4%) and 11% of patients harbored pathogenic BRCA2 germline mutations. The genomic landscape of MBC to some extent recapitulated that of smFBC, with recurrent PIK3CA (36%) and GATA3 (15%) somatic mutations, and with 40% of the most frequently amplified genes overlapping between both sexes. TP53 (3%) somatic mutations were significantly less frequent in MBC compared to smFBC, whereas somatic mutations in genes regulating chromatin function and homologous recombination deficiency-related signatures were more prevalent. MDM2 amplifications were frequent (13%), correlated with protein overexpression (P = 0.001) and predicted poor outcome (P = 0.007). In conclusion, despite similarities in the genomic landscape between MBC and smFBC, MBC is a molecularly unique and heterogeneous disease requiring its own clinical trials and treatment guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.